Fomento Economico Mexicano stock rating upgraded by UBS on Oxxo growth

UBS upgraded Fomento Economico Mexicano (FEMSA) to Buy from Neutral, adjusting its price target to 205.00 pesos from 215.00 pesos, based on an extensive review of Oxxo's value proposition and a belief that market concerns regarding structural risks are overstated. The firm anticipates significant operational improvement for Oxxo, projecting same-store sales recovery to approximately 5% by late 2025/early 2026 and high-single-digit EBITDA CAGR through 2027, which contrasts with current market expectations. UBS considers FEMSA Retail's implied 8x 2026 estimated EBITDA attractive, with upcoming same-store sales figures expected to be a near-term catalyst.

Analysis

UBS has upgraded Fomento Economico Mexicano (FMX) to Buy from Neutral, signaling a strong contrarian view that market concerns regarding structural risks to its Oxxo retail division are overstated. Although the price target was moderately adjusted down to 205.00 pesos from 215.00 pesos, the upgrade is underpinned by a forecast for significant operational improvements. UBS projects a recovery in same-store sales to approximately 5% by late 2025, driven by stabilizing macroeconomic conditions and 1,300 planned new store openings in 2025, which would expand the sales area by 4-5%. Crucially, the firm's model anticipates a high-single-digit EBITDA CAGR for 2025-2027, a stark contrast to the market's consensus expectation of low-single-digit growth. UBS views FEMSA Retail's implied valuation of 8x 2026 estimated EBITDA as attractive and identifies the release of upcoming same-store sales figures as the next key catalyst for the stock.

Key Decisions for Investors

• Investors should consider the contrarian bull thesis for FMX, as UBS's upgrade is based on growth projections (high-single-digit EBITDA CAGR) that are notably above current market consensus.
• The next earnings report is a critical catalyst; traders and investors should closely monitor same-store sales data to validate or challenge UBS’s optimistic outlook.
• Given the view that the stock's implied 8x 2026 EBITDA valuation is attractive, current price levels may present a favorable entry point for investors who believe the market has overly discounted Oxxo's growth and profitability potential.